Summary of supporting information This file includes:
Figure S1-S23: distribution of somatic mutations across the chromosomes for 23 major human cancers by 'rainfall' plots. 
Statistical significance analysis on cancer-specific mutation frequency of genes

Statistical significance analysis on frequency of arginine (R) substitution
Other material as separate files: Table S1 : a summary of the COSMIC v68 and the data used in this study. Table S2 : top frequently mutated genes in general and across cancer types. q3  q4  q5  q6  q7  q8  q9  q10  q11  q12  q13  q14  q15  q16  q17  q18  q19  q20  q21  q22  X  Y  other 2 3 6 6 4 1 9 7 2 4 1 1 5 7 2 8 7 0 0 1 1 4 8 3 1 0 6 6 8 1 2 1 9 8 9 4 9 3 7 0 3 6 8 3 0 5 1 3 8 0 4 1 1 0 3 0 3 6 9 4 6 1 7 7 5 7 7 8 6 7 3 4 9 7 5 2 3 8 0 8 1 2 9 5 2 5 1 4 1 2 1 1 8 2 9 4 1 1 1 0 9 3 1 0 1 3 4
Figure S1 Mutation distribution across the chromosomes for 858 genome-wide screened lung tumor samples. Vertical axis denotes the genomic distance of each mutation from the previous mutation. q1  q2  q3  q4  q5  q6  q7  q8  q9  q10  q11  q12  q13  q14  q15  q16  q17  q18  q19  q20  q21  q22  X  Y  other 2 2 0 2 1 7 9 2 1 3 4 9 8 7 2 1 0 2 9 1 0 2 1 1 0 0 9 7 7 0 7 2 4 7 5 2 1 2 1 1 1 1 8 8 4 0 4 5 8 2 7 0 5 7 5 3 1 2 5 5 3 0 7 1 4 9 1 5 1 4 2 3 3 3 3 8 6 7 9 8 9
Figure S2 Mutation distribution across the chromosomes for 103 genome-wide screened urinary tract tumor samples. q1  q2  q3  q4  q5  q6  q7  q8  q9  q10  q11  q12  q13  q14  q15  q16  q17  q18  q19  q20  q21  q22  X  Y  other 2 0 7 1 3 1 8 9 0 8 1 3 9 4 4 9 5 2 6 1 1 5 1 9 1 1 0 5 0 1 0 7 0 9 8 3 4 2 8 2 7 9 8 3 7 9 1 2 2 3 4 1 1 6 2 7 4 7 6 6 5 7 8 0 6 2 1 4 7 5 1 6 1 0 8 8 6 3 5 9 1 1 3 4 1 1 4 9 5 6 2 1 8 7 3 5 8 6 8 6 9 2 9 8 0
Figure S3
Mutation distribution across the chromosomes for 599 genome-wide screened large intestine tumor samples. q1  q2  q3  q4  q5  q6  q7  q8  q9  q10  q11  q12  q13  q14  q15  q16  q17  q18  q19  q20  q21  q22  X  Y  other 2 4 4 4 2 2 3 1 1 5 0 8 8 9 4 1 2 7 4 1 2 6 2 1 3 7 9 1 2 9 5 9 5 8 1 0 2 2 1 6 0 2 1 2 9 1 5 5 7 6 7 2 7 3 7 8 5 4 1 3 4 4 4 3 5 1 7 5 8 6 0 3 2 1 8 3 9 0 1 0 0 1 1 4 0 Figure S4 Mutation distribution across the chromosomes for 173 genome-wide screened oesophagus tumor samples. q1  q2  q3  q4  q5  q6  q7  q8  q9  q10  q11  q12  q13  q14  q15  q16  q17  q18  q19  q20  q21  q22  X  Y  other   1 5 8 3 2 1 3 9 7 6 9 9 3 1 6 9 3 8 8 6 3 1 8 0 3 9 7 7 0 9 6 1 1 8 6 0 8 2 6 3 2 6 9 0 3 8 8 8 3 1 3 4 2 5 4 6 3 7 4 9 1 6 5 4 6 2 7 7 1 1 2 6 8 7 9 8 8 6 3 4 2 0 1 6 3 0 2 5 8 6 9 9 7 6 0 1 3 2
Figure S5
Mutation distribution across the chromosomes for 281 genome-wide screened endometrium tumor samples. q1  q2  q3  q4  q5  q6  q7  q8  q9  q10  q11  q12  q13  q14  q15  q16  q17  q18  q19  q20  q21  q22  X  Y  other 3 0 1 0 2 5 3 5 2 0 5 0 1 3 1 7 1 6 7 5 1 6 3 8 1 6 2 5 1 0 6 1 1 1 5 4 1 2 4 2 1 8 8 4 1 7 3 5 5 9 9 9 2 5 9 1 2 9 9 7 1 7 9 5 5 0 1 1 9 8 7 6 7 5 3 3 0 4 8 0 1 0 5 7 1 7 3
Figure S6 Mutation distribution across the chromosomes for 438 genome-wide screened liver tumor samples. q3  q4  q5  q6  q7  q8  q9  q10  q11  q12  q13  q14  q15  q16  q17  q18  q19  q20  q21 q22 X Y other 3 0 2 1 2 5 6 6 1 8 4 6 1 1 7 4 1 6 4 4 1 5 3 2 1 5 7 4 1 1 9 1 1 0 2 1 1 2 4 9 1 7 1 1 1 6 6 7 6 5 6 8 2 1 9 9 2 1 1 3 8 1 6 7 7 5 1 6 1 8 7 9 7 0 7 2 9 1 5 5 8 1 1 7 8 1 1 1 5 5 Figure S8 Mutation distribution across the chromosomes for 475 genome-wide screened kidney tumor samples. breast (44225) q1 q2 q3 q4 q5 q6 q7 q8 q9 q10 q11 q12 q13 q14 q15 q16 q17 q18 q19 q20 q21 q22 X Y other 4 5 8 0 3 6 3 4 2 9 1 2 1 5 2 6 2 0 5 7 2 1 9 0 2 0 5 0 1 5 4 3 1 6 2 8 1 6 1 7 2 2 6 1 2 3 6 9 7 6 7 1 1 6 4 1 2 5 3 1 5 8 0 2 7 1 3 6 9 6 2 8 4 6 1 0 4 4 3 8 2 6 6 9 2 4 7 5 4 2 6 5
Figure S10 Mutation distribution across the chromosomes for 952 genome-wide screened breast tumor samples. q3  q4  q5  q6  q7  q8  q9  q10  q11  q12  q13  q14  q15  q16  q17  q18  q19  q20  q21 q22 X Y other 6 7 6 4 9 6 4 5 6 2 9 3 3 5 9 4 6 8 3 6 8 3 1 6 2 3 3 2 7 6 4 5 9 3 7 7 1 1 1 2 2 2 1 8 9 2 2 5 5 0 6 1 0 6 5 0 9 1 5 7 6 5 1 1 8 2 7 4 4 1
Figure S12 Mutation distribution across the chromosomes for 161 genome-wide screened upper aerodigestive tract tumor samples. Figure S13 Mutation distribution across the chromosomes for 345 genome-wide screened pancreas tumor samples. q3  q4  q5  q6  q7  q8  q9  q10  q11  q12  q13  q14  q15  q16  q17  q18  q19  q20  q21  q22  X  Y  other 1 4 2 1 4 3 6 9 6 5 6 6 6 9 7 8 5 4 4 9 4 2 8 8 9 0 2 0 4 9 3 2 4 6 9 9 2 9 9 4 1 8 1 9 2 4 6 4 6 5
Figure S14 Mutation distribution across the chromosomes for 74 genome-wide screened bone tumor samples. Genomic distance (10^) eye ( Figure S15 Mutation distribution across the chromosomes for 34 genome-wide screened eye tumor samples. q1  q2  q3  q4  q5  q6  q7  q8  q9  q10  q11  q12  q13  q14  q15  q16  q17  q18  q19  q20  q21 q22 X Y other 5 1 3 4 1 7 2 7 6 2 1 0 2 5 1 2 7 6 2 4 7 1 7 8 1 7 7 1 5 5 3 4 9 3 0 4 8 9 1 1 9 1 3 6 1 5 5 3 0 8 1 0 8 4 1 0 1 1 3 4 3 1 1 9 2 1 7 3 0
Figure S16 Mutation distribution across the chromosomes for 327 genome-wide screened automatic ganglia tumor samples. q3  q4  q5  q6  q7  q8  q9  q10  q11  q12  q13  q14  q15  q16  q17  q18  q19  q20  q21  q22  X  Y  other   6 3  5 2  2 1  2 5  3 7  3 2 4 2 1 9 2 5 2 5 2 9 2 7 1 7 1 4 1 3 1 8 2 5 1 1 3 9 1 0 0 1 6 3 2 0 0
Figure S17 Mutation distribution across the chromosomes for 49 genome-wide screened salivary gland tumor samples. q1  q2  q3  q4  q5  q6  q7  q8  q9  q10  q11  q12  q13  q14  q15  q16  q17  q18  q19  q20  q21  q22 X Y other 1 6 7 1 1 5 1 5 1 1 3 3 7 5 5 9 4 9 1 0 6 6 1 0 2 4 7 3 8 7 3 3 7 2 8 1 0 3 9 1 0 9 5 3 1 0 4 2 3 5 0 7 7 0 9 1 2 5 0 4 9 5 1 2 2 4 3 9 1 2 3 6 2 9 8 7 9 4 9 3 1
Figure S18 Mutation distribution across the chromosomes for 1008 genome-wide screened haematopoietic-and-lymphoid-tissue tumor samples. Genomic distance (10^) skin (49598) q1 q2 q3 q4 q5 q6 q7 q8 q9 q10 q11 q12 q13 q14 q15 q16 q17 q18 q19 q20 q21 q22 X Y other 5 4 6 2 3 6 9 4 3 0 2 6 2 2 2 1 2 5 8 8 2 5 6 1 2 6 4 5 1 9 3 6 1 9 5 7 2 0 4 9 2 7 4 3 2 6 9 6 9 8 2 1 4 6 7 1 2 4 5 1 6 1 0 2 3 7 5 1 0 0 4 2 6 8 8 1 3 3 8 5 0 2 7 8 7 1 9 9 5 1 9 8
Figure S19 Mutation distribution across the chromosomes for 320 genome-wide screened skin tumor samples. q3  q4  q5  q6  q7  q8  q9  q10  q11  q12  q13  q14  q15  q16  q17  q18  q19  q20  q21 q22 X Y other 6 0 2 4 8 5 4 0 9 2 2 1 2 4 2 3 2 6 4 7 6 2 2 0 2 7 6 2 4 0 3 7 6 3 7 0 1 0 6 1 8 4 1 9 5 2 2 0 5 2 4 8 6 5 9 3 1 3 6 7 0 2 6 0 3 7 3 1 8 0
Figure S20 Mutation distribution across the chromosomes for 519 genome-wide screened central nervous system tumor samples. q3  q4  q5  q6  q7  q8  q9  q10  q11  q12  q13  q14  q15  q16  q17  q18  q19  q20  q21 q1  q2  q3  q4  q5  q6  q7  q8  q9  q10  q11  q12  q13  q14  q15  q16  q17  q18  q19  q20  q21 TA  TC  TD  TE  TF  TG  TH  TI  TK  TL  TM  TN  TP  TQ  TR  TS  TV  TW  TY  VA  VC  VD  VE  VF  VG  VH  VI  VK  VL  VM  VN  VP  VQ  VR  VS  VT  VW  VY FD  FE  FG  FH  FI  FK  FL  FM  FN  FP  FQ  FR  FS  FT  FV  FW  FY  GA  GC  GD  GE  GF  GH  GI  GK  GL  GM  GN  GP  GQ  GR  GS  GT  GV  GW  GY  HA  HC  HD  HE  HF  HG  HI  HK  HL  HM  HN  HP  HQ  HR  HS  HT  HV  HW  HY  IA  IC  ID  IE  IF  IG  IH  IK  IL  IM  IN  IP  IQ  IR  IS  IT  IV  IW 
Statistical significance analysis on cancer-specific mutation frequency of genes
We performed a statistical significance analysis on the top 1000 frequently genes (Table S2A) to explore their relative importance to specific cancer types. The significance for each gene is assessed based on the sample coverage and expected mutation frequency considering its sequence length. Suppose TTN (the longest protein) is mutated in a tumor sample with a probability of μ TTN , under the null hypothesis that genes are mutated randomly determined only by their protein sequence length, the probability that an arbitrary gene i will be mutated in a tumor sample can be calculated by
where L i and L TTN refer to the protein sequence length of gene i and gene TTN respectively. Since our purpose is to rank the relative importance of genes to a specific cancer, μ TTN can be set as any reasonable positive value between 0 and 1. In our practice, we set μ TTN =0.1, the order magnitude of which is comparable to the mutation frequency (/Mb) presented in (Lawrence et al., 2013, ref. 19 in main text). We obtained the sequence length by retrieving the genes in the UniProt protein database (http://www.uniprot.org/) and calculated the sequence length relative to TTN as shown in Figure S35 . We applied our previously developed gene name -accession number correspondence table (Tan et al., 2012, ref. 22) to enable a maximum coverage of the 1000 test genes by UniProt. Since genes may have many aliases, most of them (495 out of 1000) could not be directly mapped to UniProt. Using the correspondence table, only 10 could not be mapped (denoted as 'NA' in Table S2C ).
After obtained the background mutation probability of each gene, the statistical significance of each gene can be determined from the sample coverage profiles (Table S2A ) by binomial test. For a specific cancer type j, if K out of N j samples bears mutation(s) of gene i, the probability of observing m ≥ K samples with mutation(s) of gene i can be calculated as: We first adopted this formula to generate Table S2C . Then, for each individual cancer, we sorted the 1000 p-values in increasing order. The 1000 p-values corresponded to the top 1000 frequently mutated genes listed in Table S2A . Genes with equal p-values are secondarily sorted according to their frequency detected in the current COSMIC (release 68), with more frequent genes ranking higher than less frequent ones. This ranking procedure produced supplementary Table S2D .
